samedan logo
home > news > detailed info

Biopharmaceuticals company attends sector conferences in the online format

3P Biopharmaceuticals

A leading Contract Development and Manufacturing Organization (CDMO), 3P Biopharmaceuticals, specialized in process development and cGMP manufacturing of biologics, is attending the most relevant events of the sector, although in digital format, as a consequence of the cancellation of global events due to the pandemic.

COVID19 has affected everyone and all sectors. Therefore, events and conferences in the pharma and biotech sectors have also been affected. So, meanwhile, some events are postponed, others are cancelled but others are switched to digital format. This is the best way to cover the cancellation of the fairs and to be able to continue with the commercial activity.

Covid19 Virtual Partnering Event, held this year between May 4 and 6, as a platform for pharma and biotech companies to share their proposals and projects in the fight against COVID. This is the first year that 3P has participated in a virtual event and the cause deserved it. Although according to Elena Erroba, Business Development Director: " We had interesting meetings and we have to follow the evolution of the relationships with the companies identified in this event, although it is true that being at the conference face to face favours a fluid conversation and the mutual knowledge of the potential of future collaboration and in this digital format this interaction and closeness is missing".

BIO International Convention (this year BIO DIGITAL) is the leading conference of the biotech sector worldwide and one of the annual must-attend events for 3P. It is held in the United States and this year was planned to take place in San Diego in June 8-12. This is the first year that the company was going to attend as its exhibitor with a 10sqm stand but after the circumstances, it will be held in digital format. In the words of Erroba: "Attendance in digital format is the best possible solution after the cancellation or suspension of the fairs, events and other face-to-face activities we have attended up to now. It is not the same as having a booth and meetings in person but we hope to have promising meetings since this fair has always been a key element in getting to know a highly demanding market such as the American one, as well as consolidating long term relationships with companies from all over the world. "

With almost its entire portfolio composed of international clients, 3P has an active presence in the main international markets such as the United States, Germany, France, Sweden, Norway, Italy, the United Kingdom, Belgium, Switzerland, Australia, etc. Therefore, attendance at international fairs is a key part of their business strategy. Besides, according to Elena Erroba, "the conferences we attend are an essential showcase to promote interaction with clients, potential clients, companies and to consolidate our image in the international marketplace".

Other affected conferences

Bio Europe Spring was also held in digital format in March and Bio Trinity in April. But other events such as Swiss Biotech Days, Antibody Industrial Symposium or Bio Spain are some of the international events that 3P has attended during the last few years and that time have been postponed to the end of the year or even to 2021. However, Bio Europe or CPhI, scheduled for the autumn, have not yet announced any changes to the planned agenda. In any case, we will have to see how the pandemic evolves to see how the sector's fairs develop.

About 3P Biopharmaceuticals

3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development, from initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market.

For further information:
Print this page
Send to a friend
News and Press Releases

Byondis Announces Positive Topline Results of Pivotal Phase III TULIP® Study in Patients with HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Byondis B.V. today announced positive topline results from the Phase III TULIP® study, a multi-center, open-label, randomized clinical trial.
More info >>

White Papers

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement